Physician
Hematology
Dr. Borje S. Andersson, MD
|
|
Give Review
Borje S. Andersson, MD is an expert in the field of Hematology. Doctor Borje S. Andersson, MD is a published doctor as well. He has 59 publications published. The latest was: Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia. Borje S. Andersson accepts Medicare payments and is listed with Medicare.gov.
Publications
- Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
- Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors.
- Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.
- Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
- Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
- Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.
- Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hemato...
- Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: enhancement of cytotoxicity with epigenetic modu...
- Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regi...
- Can a Female Donor for a Male Recipient Decrease Relapse Rate for Patients with AML Treated with Allogeneic Hematopoietic Stem Cell Transplantation?
- Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications-Positive Acute Myeloid Leuk...
- Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation.
- Increasing Chimerism Following Allogeneic Stem Cell Transplantation is Associated with Longer Survival Time.
- The histone deacetylase inhibitor SAHA sensitizes Acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
- The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.
- Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple Myeloma: Relevance of p53 and its clinical implic...
- High-dose chemotherapy and Autologous Stem Cell Transplantation For Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
- Ex Vivo T Cell Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission.
- Cord-blood engraftment with ex vivo mesenchymal-cell coculture.
- Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome.
- High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
- Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission.
- Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell...
- IntraVenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
- Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in Lymphoma cell lines.
- Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Ty...
- Donor leukocyte infusions (DLIs) in recurrent hodgkin Lymphoma (HL) following allogeneic stem cell transplantation: ten-year experience at the M.D. anderson cancer cen...
- Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and SAHA in Lymphoma cell lines.
- Busulfan and Metronidazole: An Often Forgotten but Significant Drug Interaction (July/August).
- Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with Multiple Myeloma.
- Platelet Recovery Prior to Allogeneic Stem Cell Transplant Predicts Posttransplant Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
- IntraVenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lympho...
- Generic immunosuppressants in hematopoietic cell transplantation.
- Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with Acute myeloid leukemia or myelodysplastic ...
- Prophylaxis of graft-versus-host Disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively ra...
- Steroid-Refractory Acute GVHD: Predictors and Outcomes.
- Unrelated Donor Transplantation for Acute Myelogenous Leukemia in First Remission.
- Advances in CML: The Role of Allogeneic Hematopoietic Stem Cell Transplantation.
- Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared with One Human Le...
- Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid Leukemia and MDS.
- Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.
- Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.
- Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for Acute leukemia.
- Busulfan in hematopoietic stem cell transplantation.
- Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in...
- High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
- Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid Leukemia: no evidence for increased transplant-rel...
- Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
- Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and Acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
- Prognostic factors for outcomes of patients with refractory or relapsed Acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell t...
- Once-daily intraVenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cel...
- Nonablative versus reduced-intensity conditioning regimens in the treatment of Acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long...
- IntraVenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
- Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for Myeloid malignancies in patients older than 55 years.
- Conditioning therapy with intraVenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II s...
- Busulfan systemic exposure relative to regimen-related toxicity and Acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenou...
- IntraVenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence...
- Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in Lymphoma cell lines.
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Education
-
University of Texas MD Anderson Cancer Center -
Karolinska Institute Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1881793560 | |
| NPPES Provider LastName | ANDERSSON | |
| NPPES Provider FirstName | BORJE | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 99.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1881793560 |
| Last Name Of The Provider | ANDERSSON |
| First Name Of The Provider | BORJE |
| View All |
Similar Doctors
|
Dr. Sahba Q. Nadeem, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gautam Borthakur, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Michael H. Kroll, MD |
|
|
Dr. Elena G. Nedelcu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Don L. Gibbons Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ming-Sheng Lee, MD |
|
|
Dr. Wei Lin, MD |
|
|
Dr. Abhishek V. Marballi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tara N. Miller, MD |
|
|
Dr. Brittany K. Ragon, MD |
|
|
Dr. Parijatham S. Thomas, MD
This Doctor is OpenDoctor Recommended.
|